FN3KRP Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from Raji B lymphocytes, featuring targeted disruption of the FN3KRP gene. This pooled knockout model provides a heterogeneous population of cells with FN3KRP loss-of-function, suitable for studying gene function without clonal selection bias. The polyclonal format ensures representation of multiple mutational events, offering a robust functional genomics tool.
The Raji cell line is a well-characterized human B-lymphocyte model established from a Burkitt??s lymphoma patient. These cells are Epstein-Barr virus (EBV)-positive and exhibit a lymphoblastoid morphology, making them a valuable system for investigating B-cell malignancies and immune cell biology. Raji cells are widely used in cancer research, immunology, and drug discovery due to their robust growth and well-defined signaling networks. Their EBV-positive status also enables studies of viral oncogenesis and host-virus interactions.
FN3KRP encodes fructosamine-3-kinase-related protein, an enzyme that phosphorylates fructosamines such as fructoselysine, initiating their deglycation and detoxification. This activity prevents the accumulation of advanced glycation end-products (AGEs), which are implicated in diabetic complications and metabolic disorders. FN3KRP expression is regulated by the MondoA (MLXIP)-Mlx transcription factor complex, which responds to intracellular glucose levels. Upon glucose stimulation, MondoA-Mlx translocates to the nucleus and promotes FN3KRP transcription. The enzyme functions in concert with FN3K, sharing overlapping substrate specificities, and its activity leads to the formation of fructosamine-3-phosphate, which is subsequently processed to non-reactive species. Thus, FN3KRP operates within the protein deglycation pathway, mitigating glycation stress.
In the context of Raji B cells, FN3KRP knockout provides a unique tool to study how impaired deglycation impacts lymphoma biology. B-cell malignancies may exhibit altered glucose metabolism and glycation patterns, potentially affecting cell survival and proliferation. Disrupting FN3KRP in this EBV-positive background allows researchers to dissect the role of AGE detoxification in lymphomagenesis and to evaluate the interplay between metabolic stress and oncogenic signaling. This model is particularly relevant for investigating how glycation-related pathways contribute to the pathogenesis of Burkitt??s lymphoma and other B-cell cancers.
Researchers can employ FN3KRP Knockout Raji Polyclonal Cells to perform a variety of functional assays, including Western blotting and RT-qPCR to confirm loss of FN3KRP expression, fructosamine kinase activity assays to measure enzymatic function, and AGE quantification to assess glycation product levels. Additionally, cell viability and glucose uptake assays can reveal metabolic consequences of the knockout, while MondoA reporter assays enable examination of transcriptional regulation. These applications make the cells suitable for exploring diabetic complications, metabolic syndrome, and glycation-associated disorders in an immune cell context. For further details or to inquire about custom services, please contact Ascent Research.
